ДЗЕ РИСЕРЧ ФАУНДЕЙШН ФОР ДЗЕ СТЕЙТ ЮНИВЕРСИТИ ОФ НЬЮ ЙОРК (US)
发明人:
БРУКСОН Сабин (US),КИРКАНИДЕС Стефанос (US)
申请号：
RU2014141114
公开号：
RU2014141114A
申请日:
2013.03.15
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A pharmaceutical composition comprising a first agent and a second agent, wherein: the first agent is specifically targeted to one or more of the second, third, fourth or fifth sub-domains (EC2, EC3, EC4 and EC5, respectively) of the ectodomain of E-cadherin or a fragment thereof - soluble E-cadherin (sEcad), but is not aimed at the first subdomain (EC1) of the ectodomain of E-cadherin or sEcad second agent inhibits HER1, provided that cetuximab and panitumumab excluded It inhibits HER2, with the proviso that trastuzumab deleted inhibits HER3 inhibits HER4 or inhibits the receptor at one of the following families of receptors: A family of VEGFR, family of PDGFR, the family of FGF, HGF family, family Trk receptor family of Eph receptor family AXL receptor family of TIE receptor family receptor RET, family receptor MuSK or family IGFR receptors ikolichestva first and second agents taken together are therapeutically effektivnymi.2. A pharmaceutical composition according to Claim. 1, wherein the first agent is a protein karkas.3. . The pharmaceutical composition according to claim 2, in which the carcass is an antibody or biologically active fragment thereof that specifically binds an epitope comprising amino acid residues at one or more subdomains of EC2, EC3, EC4 and EC5 ectodomain of E-cadherin or a fragment thereof - soluble E- cadherin (sEcad), but not in the EC1 subdomain sEcad.4. A pharmaceutical composition according to Claim. 1, wherein the second agent is a protein karkas.5. A pharmaceutical composition according to claim. 4, wherein the protein specifically binds a frame and inhibits HER1, HER2, HER3, HER4 or kombinatsiyu.6. A pharmaceutical composition according to Claim. 1, wherein the composition kills malignant E-cadherin-expressing cells, but does not destroy nezlokachestve1. Фармацевтическая композиция, содержащая первый агент и второй агент, в которой:первый агент специфически нацелен на один или несколько из второго, третьего, четвертого или пятого
